INDIANAPOLIS (United States) – It was called LY-COV555 the antibody identified by the Vaccine Research Center of the National Institute of Allergies and Infectious Diseases and developed in just three months by the pharmaceutical company Eli Lilly in collaboration with AbCellera: the drug under study has already been tested on some patients and, technically, it will be usable in both prevention and treatment. The results are expected by tight mail (by June 30th).
“It will be important for the elderly”
“We are committed to working with industry partners to generate scientific evidence that can satisfy the urgent need for treatments that reduce the severity of the disease. Antibody treatments, such as the one studied here, promise to be effective countermeasures against this deadly infection“, he has declared Mark J. Mulligan, director of the division of infectious diseases and immunology and director of the Vaccine Center at NYU Langone Health. For Daniel Skovronsky, Chief Scientific Officer and president of Lilly Research Laboratories, is the “first potential new drug specifically designed to fight the virus. Antibody therapies such as LY-CoV555 can prove effective in both prevention and treatment and can be particularly important for groups most affected by the disease such as the elderly and people with compromised immune systems. By the end of the month, we will review the results of this first human study and intend to launch larger efficacy studies“.